Oftamirin eye/ear/nasal drops, solution 0.1 mg/mL, 5 mL per bottle
Ingredients
Active ingredient: miramistin;
1 mL of solution contains 0.1 mg of miramistin;
excipients: sodium chloride, disodium phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate, water for injection.
Dosage Form
Eye/ear/nasal drops.
Main physical and chemical properties: colorless, clear liquid.
Pharmacotherapeutic group
Agents used in ophthalmology and otology. Decongestants and other preparations for topical use in diseases of the nasal cavity. ATC code S03D, R01A.
Pharmacological properties
Pharmacodynamics.
Miramistin is a cationic surfactant with antimicrobial (antiseptic) activity.
The mechanism of action of miramistin is based on the direct hydrophobic interaction of the molecule with the lipids of microbial membranes, leading to their fragmentation and destruction. In this process, a portion of the miramistin molecule, upon penetrating the hydrophobic region of the membrane, disrupts the outer membrane layer, destabilizes the membrane, increases its permeability to high-molecular-weight substances, alters the enzymatic activity of the microbial cell, and inhibits enzyme systems, resulting in the suppression of microbial vital functions and their cytolysis.
Unlike other antiseptics, miramistin exhibits high selectivity against microorganisms, as it has virtually no effect on human cell membranes. This effect is due to the different structure of human cell membranes (which have significantly longer lipid chains, sharply limiting the possibility of hydrophobic interaction between miramistin and human cells).
Miramistin exerts a pronounced antimicrobial effect against Gram-positive and Gram-negative, aerobic and anaerobic, spore-forming and non-spore-forming bacteria, whether in monocultures or microbial communities, including hospital strains with multidrug resistance to antibiotics.
It is lethal to pathogens that cause sexually transmitted diseases—Neisseria gonorrhoeae, Treponema pallidum, Trichomonas, Chlamydia—as well as herpes viruses, human immunodeficiency viruses, and others. It has antifungal activity against ascomycetes of the genera Aspergillus and Penicillium, yeasts (Rhodotorula rubra, Torulopsis gabrata, etc.) and yeast-like fungi (Candida albicans, Candida krusei, etc.), dermatophytes (Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton verrucosum, T. schoenleini, T. violaceum, Epidermophyton Kaufman-Wolf, E. floccosum, Microsporum gypseum, Microsporum canis, etc.), as well as other pathogenic fungi (e.g., Pityrosporum orbiculare (Malassezia furfur)) in the form of monocultures and microbial associations, including fungal microflora resistant to chemotherapeutic agents. Under the action of miramistin, the resistance of microorganisms to antibiotics is reduced.
Miramistin has anti-inflammatory and immunostimulatory effects, enhances local defense reactions and regenerative processes, and activates nonspecific defense mechanisms by modulating cellular and local humoral immune responses, thereby accelerating recovery.
Pharmacokinetics.
Miramistin exerts a local effect. There are no data on the drug’s potential to enter the systemic circulation.
Indications
For the comprehensive treatment of infectious processes of the anterior segment of the eye (blepharitis, conjunctivitis, keratitis, keratouveitis) caused by Gram-positive and Gram-negative bacteria, chlamydia, fungi, and viruses sensitive to miramistin, as well as eye injuries and eye burns (thermal and chemical).
Prevention of neonatal ophthalmia, including gonococcal and chlamydial forms. Prevention and treatment of purulent-inflammatory eye lesions during the pre- and postoperative periods.
As part of the comprehensive treatment of acute and chronic external otitis, chronic purulent mesotympanitis, and otomycosis.
For the comprehensive treatment of acute rhinitis.
Contraindications
Hypersensitivity to miramistin or to any other components of the drug.
Interactions with Other Medications and Other Types of Interactions
When used concomitantly, Oftamirine enhances the efficacy of topical antibiotics. Inform your doctor if you are taking any other medications at the same time.
Special Considerations
Use during pregnancy or breastfeeding.
This medication may be used during pregnancy or while breastfeeding.
Effect on reaction time when driving or operating machinery.
This medication does not affect reaction time when driving or operating machinery.
Dosage and Administration
Ophthalmology.
For the treatment of infections of the anterior segment of the eye, adults and children 12 years of age and older should instill 2–3 drops into the conjunctival sac; children under 12 years of age should instill 1–2 drops 4–6 times daily. The duration of treatment usually does not exceed 2 weeks.
To prevent complications during the pre- and postoperative periods, instill 2–3 drops 3 times daily starting 2–3 days before surgery. After surgery, instill 1–2 drops 3 times daily for 3–5 days.
When treating eye burns, after rinsing the eye with plenty of water, administer frequent instillations (every 5–10 minutes) for 1–2 hours. For further treatment, administer 2–3 drops to adults and children 12 years of age and older, and 1–2 drops to children under 12 years of age, 4–6 times a day.
To prevent ophthalmia in newborns, immediately after birth, instill 1 drop of the medication into each eye 3 times at 2–3-minute intervals.
Otolaryngology.
For the treatment of acute and chronic otitis externa and otomycosis
adults and children 12 years of age and older should use 3–5 drops 4–6 times a day;
for children under 12 years of age—2–3 drops 4–6 times a day.
A gauze tampon moistened with the medication may be inserted into the external auditory canal 4–6 times a day for 10–14 days (instead of instillation).
For chronic mesotympanitis, use as part of a comprehensive treatment regimen via ultrasonic irrigation or instillation into the tympanic cavity together with antibiotics.
For the treatment of acute rhinitis and infections of the nasal mucosa, instill 2–3 drops in adults and children 12 years of age and older; and 1–2 drops into each nostril for children under 12 years of age, 4–6 times daily. The course of treatment is 7–14 days.
Dosage Instructions. The exact dosage is achieved by pressing the bottom of the bottle—1 press = 1 drop.
Children.
This medication may be used in pediatric practice.
Overdose
No cases of overdose have been reported.
Side Effects
Hypersensitivity reactions may occur with the use of this medication. In some cases, a brief burning sensation may occur, which resolves on its own within 5–20 seconds and does not require discontinuation of treatment.
Shelf Life
3 years.
Do not use this medication after the expiration date printed on the package or if the “first-opening” seal has been broken.
Once the vial is opened, the medication should be used within 28 days.
Storage Conditions
Store in the original packaging out of the reach of children at a temperature not exceeding 30 °C.
Keep the vial tightly closed between uses.
Packaging
5 mL of the drug per vial; 1 vial per pack.
Dispensing Category: By prescription only.
Manufacturer
PJSC “Darnitsa Pharmaceutical Company.”
Address
Ukraine, 02093, Kyiv, 13 Boryspilskaya St.
Similar products
Products from the same category











